Market Newsdesk

Call scheduled for 8:00 AM ET on Monday, November 24, 2025

UGI Reports Strong Fiscal 2025 Results

Issues Fiscal 2026 Guidance

VALLEY FORGE, Pa.–(BUSINESS WIRE)–
UGI Corporation (NYSE: UGI) today reported financial results for the fiscal year ended September 30, 2025 and provided guidance for fiscal year 2026.

HEADLINES

• GAAP net income of $678 million and adjusted net income of $728 million compared to GAAP net income of $269 million and adjusted net income of $658 million in the prior year.

• GAAP diluted earnings per share (“EPS”) of $3.09 and adjusted diluted EPS of $3.32 compared to GAAP diluted EPS of $1.25 and adjusted diluted EPS of $3.06 in the prior year.

• Reportable segments earnings before interest expense and income tax¹ (“EBIT”) of $1,176 million compared to $1,178 million in the prior year.

• Delivered adjusted diluted EPS above the top end of our revised guidance range issued on May 7, 2025.

• Strengthened the balance sheet with available liquidity of approximately $1.6 billion and a leverage ratio of 3.9x at UGI Corporation and 4.9x at AmeriGas Propane.

• Issues fiscal 2026 adjusted diluted EPS guidance range of $2.90 – $3.15², inclusive of an expected 5 – 7% growth in reportable segments EBIT.

• Increases and extends its expected EPS compound annual growth rate to 5 – 7% between FY24 and FY29.

“UGI delivered an outstanding year with record adjusted earnings per share that exceeded our revised guidance range,” said Robert Flexon, President and Chief Executive Officer of UGI Corporation. “Our diversified portfolio demonstrated its strength as continued improvements at AmeriGas which led to its higher EBIT coupled with solid operational performance from our Utilities segment, and significant tax benefits, drove exceptional results. We strengthened our balance sheet, generated approximately $530 million of free cash flow inclusive of cash generated from asset sales, and returned value to shareholders through dividend payments.

“This year, we invested in upskilling our workforce and cultivating a performance-driven culture focused on driving breakthrough outcomes in our operating and supporting functions. This foundation is crucial as we enhance our operating processes, transform how we work across the organization, and optimize UGI’s intrinsic value for all stakeholders. I am particularly excited about the progress we’ve made at AmeriGas and anticipate that the winter season ahead will demonstrate the tangible impact of the initiatives underway.”

2026 OUTLOOK

UGI provides an adjusted EPS guidance range of $2.90 – $3.15² per diluted share for the fiscal year ending September 30, 2026. This guidance range assumes normal weather and the current tax regime.

EARNINGS CALL and WEBCAST

UGI Corporation will hold a live Internet Audio Webcast of its conference call to discuss Fiscal 2025 earnings and other current activities at 9:00 AM ET on Friday, November 21, 2025. Interested parties may listen to the audio webcast both live and in replay on the Internet at https://www.ugicorp.com/investors/financial-reports/presentations or by visiting the company website https://www.ugicorp.com and clicking on Investors and then Presentations. A replay of the webcast will be available after the event through to 11:59 PM ET November 19, 2026.

ABOUT UGI

UGI Corporation (NYSE: UGI) is a distributor and marketer of energy products and services in the US and Europe. UGI offers safe, reliable, affordable, and sustainable energy solutions to customers through its subsidiaries, which provide natural gas transmission and distribution, electric generation and distribution, midstream services, propane distribution, renewable natural gas generation, distribution and marketing, and energy marketing services.

Comprehensive information about UGI Corporation is available on the Internet at https://www.ugicorp.com.

USE OF NON-GAAP MEASURES

Management uses “adjusted net income attributable to UGI Corporation” and “adjusted diluted earnings per share,” both of which are non-GAAP financial measures, when evaluating UGI’s overall performance. Management believes that these non-GAAP measures provide meaningful information to investors about UGI’s performance because they eliminate the impacts of (1) gains and losses on commodity and certain foreign currency derivative instruments not associated with current-period transactions and (2) other significant discrete items that can affect the comparison of period-over-period results. Volatility in net income attributable to UGI can occur as a result of gains and losses on commodity and certain foreign currency derivative instruments not associated with current-period transactions but included in earnings in accordance with U.S. generally accepted accounting principles (“GAAP”).

Non-GAAP financial measures are not in accordance with, or an alternative to, GAAP and should be considered in addition to, and not as a substitute for, the comparable GAAP measures.

Tables on the last page of this press release reconcile net income attributable to UGI Corporation, the most directly comparable GAAP measure, to adjusted net income attributable to UGI Corporation, and diluted earnings per share, the most comparable GAAP measure, to adjusted diluted earnings per share, to reflect the adjustments referred to above.

¹Reportable segments’ EBIT represents an aggregate of our reportable operating segment level EBIT as determined in accordance with GAAP.

²Because we are unable to predict certain potentially material items affecting diluted earnings per share on a GAAP basis, principally mark-to-market gains and losses on commodity and certain foreign currency derivative instruments, we cannot reconcile the fiscal year 2026 adjusted diluted earnings per share, a non-GAAP measure, to diluted earnings per share, the most directly comparable GAAP measure, in reliance on the “unreasonable efforts” exception set forth in SEC rules.

USE OF FORWARD-LOOKING STATEMENTS

This press release contains statements, estimates and projections that are forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended). Such statements use forward-looking words such as “believe,” “plan,” “anticipate,” “continue,” “estimate,” “expect,” “may,” or other similar words and terms of similar meaning, although not all forward-looking statements contain such words. These statements discuss plans, strategies, events or developments that we expect or anticipate will or may occur in the future. Management believes that these are reasonable as of today’s date only. Actual results may differ significantly because of risks and uncertainties that are difficult to predict and many of which are beyond management’s control; accordingly, there is no assurance that results will be realized. You should read UGI’s Annual Report on Form 10-K for a more extensive list of factors that could affect results. We undertake no obligation (and expressly disclaim any obligation) to update publicly any forward-looking statement, whether as a result of new information or future events, except as required by the federal securities laws.

SEGMENT RESULTS ($ in millions, except where otherwise indicated)

Utilities

For the year ended September 30,			2025				2024			Increase (Decrease)
Revenues		$	1,761			$	1,598			$	163		10	%
Total margin (a)		$	963			$	924			$	39		4	%
Operating and administrative expenses		$	388			$	363			$	25		7	%
Operating income		$	397			$	394			$	3		1	%
Earnings before interest expense and income taxes		$	403			$	400			$	3		1	%
Gas Utility system throughput – billions of cubic feet
Core market			102				93				9		10	%
Total			378				378				—		—	%
Natural gas heating degree days – % warmer than normal			(2.4	)%			(16.0	)%
Capital expenditures		$	556			$	482			$	74		15	%

• Temperatures were 2% warmer than normal and 11% colder than the prior year.

• Core market volumes were 10% higher largely reflecting the impact from the colder weather compared to the prior year.

• Total margin increased $39 million primarily due to higher core market volumes, higher gas base rates in West Virginia, and continued customer growth.

• Operating and administrative expenses increased $25 million reflecting, among other things, higher personnel expenses, higher general insurance costs and higher maintenance expenses.

• Operating income increased $3 million due to the higher total margin largely offset by higher operating and administrative expenses and higher depreciation expense ($12 million) from continued distribution system capital expenditure activity.

(a)

Total margin represents total revenue less total cost of sales. In the case of the Utilities, total margin is also reduced by certain revenue-related taxes.

Midstream & Marketing

For the year ended September 30,			2025				2024			Increase (Decrease)
Revenues		$	1,483			$	1,369			$	114			8	%
Total margin (a)		$	494			$	505			$	(11	)		(2	)%
Operating and administrative expenses		$	129			$	125			$	4			3	%
Operating income		$	288			$	301			$	(13	)		(4	)%
Earnings before interest expense and income taxes		$	293			$	313			$	(20	)		(6	)%
Heating degree days – % warmer than normal			(0.4	)%			(13.3	)%
Capital expenditures		$	114			$	150			$	(36	)		(24	)%

• Temperatures were 12% colder than the prior year and fairly consistent with normal weather.

• Total margin decreased $11 million reflecting lower midstream margins ($22 million), mainly from lower natural gas gathering and processing activities, and the absence of power generation associated with Hunlock that was sold in September 2024 ($16 million). These decreases were partially offset by higher total margin from gas marketing activities ($20 million).

• Operating and administrative expenses increased $4 million reflecting, among other things, additional assets placed in service this year.

• Operating income decreased $13 million due to lower total margin and higher operating and administrative expenses.

• EBIT decreased $20 million primarily due to the decrease in operating income ($13 million) and lower income from equity investees ($4 million).

UGI International

For the year ended September 30,			2025				2024			Increase (Decrease)
Revenues		$	2,119			$	2,279			$	(160	)		(7	)%
Total margin (a)		$	940			$	978			$	(38	)		(4	)%
Operating and administrative expenses		$	543			$	578			$	(35	)		(6	)%
Operating income		$	305			$	311			$	(6	)		(2	)%
Earnings before interest expense and income taxes		$	314			$	323			$	(9	)		(3	)%
LPG retail gallons sold (millions)			698				725				(27	)		(4	)%
Heating degree days – % warmer than normal			(3.3	)%			(11.8	)%
Capital expenditures		$	93			$	87			$	6			7	%

Base-currency results are translated into U.S. dollars based upon exchange rates experienced during the reporting periods. The functional currency of a significant portion of our UGI International results is the euro and, to a much lesser extent, the British pound sterling. During Fiscal 2025 and Fiscal 2024, the average unweighted euro-to-dollar translation rates were $1.11 and $1.08, respectively, and the average unweighted British pound sterling-to-dollar translation rate were $1.31 and $1.27, respectively.

• Temperatures were 3% warmer than normal and 5% colder than the prior-year.

• Retail volumes were 4% lower than the prior-year period largely due to continued structural conservation and the absence of certain customers who previously converted from natural gas to LPG, substantially offset by the effects of colder weather and higher crop drying campaigns.

• Total margin decreased $38 million reflecting lower retail gallons, partially offset by higher average LPG unit margins and the translation effects of the stronger foreign currencies ($9 million).

• Operating and administrative expenses decreased $35 million primarily due to lower personnel-related, distribution, maintenance and uncollectible account expenses, as well as from the exit of the energy marketing business. These decreases were partially offset by the translation effects of the stronger foreign currencies ($10 million).

• Operating income decreased $6 million due to lower total margin ($38 million), partially offset by lower operating and administrative expenses ($35 million) and higher depreciation and amortization expense ($4 million).

• EBIT decreased $9 million reflecting reduced operating income and lower realized gains on foreign currency exchange contracts ($5 million).

AmeriGas Propane

For the year ended September 30,			2025				2024			(Decrease) increase
Revenues		$	2,276			$	2,271			$	5			—	%
Total margin (a)		$	1,222			$	1,212			$	10			1	%
Operating and administrative expenses		$	924			$	933			$	(9	)		(1	)%
Operating income / earnings before interest expense and income taxes		$	166			$	142			$	24			17	%
Retail gallons sold (millions)			733				737				(4	)		(1	)%
Heating degree days – % warmer than normal			(1.3	)%			(8.0	)%
Capital expenditures		$	81			$	86			$	(5	)		(6	)%

• Temperatures were 1% warmer than normal and 6% colder than the prior year.

• Retail gallons sold decreased slightly as the effect of the colder than prior year weather was offset by customer attrition.

• Total margin increased $10 million reflecting higher average LPG unit margins partially offset by lower fee income and slightly lower retail volumes sold.

• Operating and administrative expenses decreased $9 million reflecting, among other things, lower uncollectible account expenses and vehicle fuel costs.

• Operating income and EBIT increased $24 million largely due to higher total margin, reduced operating and administrative expenses and higher other operating income ($5 million), mainly resulting from higher gains on sales of fixed assets.

REPORT OF EARNINGS – UGI CORPORATION

(Millions of dollars, except per share) Unaudited		Three Months Ended September 30,								Twelve Months Ended September 30,
			2025				2024				2025				2024
Revenues:
Utilities		$	216			$	202			$	1,761			$	1,598
Midstream & Marketing			251				239				1,483				1,369
UGI International			394				426				2,119				2,279
AmeriGas Propane			367				402				2,276				2,271
Corporate & Other (a)			(31	)			(27	)			(352	)			(307	)
Total revenues		$	1,197			$	1,242			$	7,287			$	7,210
Earnings (loss) before interest expense and income taxes:
Utilities		$	(9	)		$	—			$	403			$	400
Midstream & Marketing			17				15				293				313
UGI International			18				18				314				323
AmeriGas Propane			(34	)			(40	)			166				142
Total reportable segments			(8	)			(7	)			1,176				1,178
Corporate & Other (a)			27				(249	)			(69	)			(444	)
Total earnings (loss) before interest expense and income taxes			19				(256	)			1,107				734
Interest expense:
Utilities			(25	)			(24	)			(100	)			(93	)
Midstream & Marketing			(14	)			(12	)			(49	)			(41	)
UGI International			(12	)			(11	)			(46	)			(44	)
AmeriGas Propane			(38	)			(34	)			(144	)			(156	)
Corporate & Other, net (a)			(17	)			(17	)			(72	)			(60	)
Total interest expense			(106	)			(98	)			(411	)			(394	)
Income (loss) before income taxes			(87	)			(354	)			696				340
Income tax benefit (expense )			74				81				(18	)			(71	)
Net income (loss) attributable to UGI Corporation			(13	)			(273	)			678				269
Earnings (loss) per share attributable to UGI Corporation shareholders:
Basic		$	(0.06	)		$	(1.27	)		$	3.15			$	1.27
Diluted		$	(0.06	)		$	(1.27	)		$	3.09			$	1.25
Weighted Average common shares outstanding (thousands):
Basic			215,093				214,905				214,945				211,309
Diluted			221,372				215,368				219,160				215,271
Supplemental information:
Net income (loss) attributable to UGI Corporation:
Utilities		$	(23	)		$	(17	)		$	237			$	237
Midstream & Marketing			11				4				269				238
UGI International			13				49				242				262
AmeriGas Propane			20				(40	)			36				(23	)
Corporate & Other (a)			(34	)			(269	)			(106	)			(445	)
Total net income (loss) attributable to UGI Corporation		$	(13	)		$	(273	)		$	678			$	269

(a)

Corporate & Other includes specific items attributable to our reportable segments that are not included in profit measures used by our chief operating decision maker in assessing our reportable segments’ performance or allocating resources. These specific items are shown in the section titled “Non-GAAP Financial Measures – Adjusted Net Income Attributable to UGI and Adjusted Diluted Earnings Per Share” below. Corporate & Other also includes the elimination of certain intercompany transactions.

Non-GAAP Financial Measures – Adjusted Net Income Attributable to UGI and Adjusted Diluted Earnings Per Share

(unaudited)

The following tables reconcile net income attributable to UGI Corporation, the most directly comparable GAAP measure, to adjusted net income attributable to UGI Corporation, and reconcile diluted earnings per share, the most comparable GAAP measure, to adjusted diluted earnings per share, to reflect the adjustments referred to previously:

Fiscal Year Ended September 30,		2025				2024
Adjusted net income attributable to UGI Corporation (millions):
Net income attributable to UGI Corporation	$	678			$	269
Net losses (gains) on commodity derivative instruments not associated with current-period transactions (net of tax of $(2) and $17, respectively)		7				(60	)
Unrealized losses (gains) on foreign currency derivative instruments (net of tax of $(3) and $(9), respectively)		7				22
Loss associated with impairment of AmeriGas Propane goodwill (net of tax of $0 and $(3), respectively)		—				192
Loss on extinguishments of debt (net of tax of $(2) and $(3), respectively)		8				6
AmeriGas operations enhancement for growth project (net of tax of $0 and $(6), respectively)		—				19
Restructuring costs (net of tax of $0 and $(20), respectively)		—				56
Costs associated with exit of the UGI International energy marketing business (net of tax of $0 and $(15), respectively)		—				69
Net loss on disposals of businesses (net of tax of $2 and $(11), respectively)		38				55
Impairments of equity method investments and assets (net of tax of $0 and $(3), respectively)		—				30
Release of valuation allowance on certain deferred tax assets		(10	)			—
Total adjustments (1) (2)		50				389
Adjusted net income attributable to UGI Corporation	$	728			$	658
Adjusted diluted earnings per share:
UGI Corporation earnings per share – diluted	$	3.09			$	1.25
Net losses (gains) on commodity derivative instruments not associated with current-period transactions		0.03				(0.28	)
Unrealized losses (gains) on foreign currency derivative instruments		0.04				0.10
Loss associated with impairment of AmeriGas Propane goodwill		—				0.89
Loss on extinguishments of debt		0.04				0.03
AmeriGas operations enhancement for growth project		—				0.09
Restructuring costs		—				0.26
Costs associated with exit of the UGI International energy marketing business		—				0.32
Net loss on disposals of businesses		0.17				0.26
Impairments of equity method investments and assets		—				0.14
Release of valuation allowance on certain deferred tax assets		(0.05	)			—
Total adjustments (1)		0.23				1.81
Adjusted diluted earnings per share	$	3.32			$	3.06

(1)		Corporate & Other includes certain adjustments made to our reporting segments in arriving at net income attributable to UGI Corporation. These adjustments have been excluded from the segment results to align with the measure used by our chief operating decision maker in assessing segment performance and allocating resources.
(2)		Income taxes associated with pre-tax adjustments determined using statutory business unit tax rates.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20251120384086/en/

INVESTOR RELATIONS

Tel: +1 610-337-1000

Tameka Morris, ext. 6297

Arnab Mukherjee, ext. 7498

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Energy Other Energy Oil/Gas

MEDIA:

Logo

Solmate Infrastructure (Brera Holdings, PLC, NASDAQ: SLMT) Announces Strategic Partnership with Abu Dhabi Finance Week 2025

ABU DHABI, United Arab Emirates & DUBLIN–(BUSINESS WIRE)–
Solmate Infrastructure (NASDAQ: SLMT) (“Solmate,” “the Company”), the Abu Dhabi-based Solana infrastructure company, today announced that the Company will serve as an official Strategic Partner of Abu Dhabi Finance Week (ADFW), taking place 8–11 December 2025.

Abu Dhabi Finance Week 2025 is the Middle East’s premier financial and investment summit, gathering over 20,000 participants, 1,000+ institutional investors, and 500+ speakers to shape the future of finance under the theme “Capital of Capital: Powering the Future of Finance.”

The agreement underscores Solmate’s growing leadership in Middle East blockchain infrastructure and its commitment to deliver blockchain-based solutions aligned with the region’s digital transformation agenda. Solmate recently launched the first-ever bare metal Solana validator in the UAE, which is the first performant Solana validator in the Middle East and expected to rank among the top Solana validators globally.

At the Summit, Solmate CEO Marco Santori will deliver a keynote address outlining the company’s current and future plans to support Abu Dhabi’s position as the leader in digital asset infrastructure. The keynote will take place on December 10, 2025.

Marco Santori, Chief Executive Officer of Solmate Infrastructure, commented:

“Abu Dhabi is rapidly establishing itself as the global capital for the digital age. Partnering with ADFW at the strategic level gives us the perfect platform to showcase how Solana’s high-performance infrastructure, combined with real-world institutional-grade treasury and staking solutions, is accelerating the convergence of traditional and decentralized finance. We’re proud to stand shoulder-to-shoulder with ADGM as we build the financial rails of tomorrow — right here in the UAE.”

About Solmate Infrastructure (NASDAQ: SLMT)

Solmate Infrastructure, the new operating name of Brera Holdings, PLC (NASDAQ: SLMT), is an Abu Dhabi-headquartered company building institutional-grade Solana staking, validation, and treasury infrastructure. Backed by ARK Invest, RockawayX, Pulsar Group, and leading UAE investors, Solmate is deploying capital and hardware to drive Solana adoption across the Middle East and beyond. It will continue to operate Brera’s multi-club football team model. For more information visit www.solmate.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251120935933/en/

Media Contacts

Solmate Infrastructure

Marco Santori

[email protected]

KEYWORDS: Europe Ireland United Arab Emirates Middle East

INDUSTRY KEYWORDS: Professional Services Technology Blockchain Cryptocurrency Software Hardware

MEDIA:

Posted on November 20, 2025 6:06 pm

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)–
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that following the announcement on November 14, 2025 of the entering into of a definitive arrangement agreement with XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly, “Xeno”), a non-profit biotechnology company, pursuant to which Xeno will acquire (the “Transaction”) all of the issued and outstanding common shares of Repare (the “Common Shares”), certain entities affiliated with BVF Partners L.P., Blue Owl Healthcare Opportunities, and certain entities affiliated with OrbiMed have each entered into a support and voting agreement pursuant to which they have agreed to vote their Common Shares in favor of the special resolution approving the Transaction.

Considering the previously announced support and voting agreements entered into by the directors and executive officers of Repare, shareholders owning approximately 40% of Repare’s issued and outstanding Common Shares have now agreed to vote their Common Shares in favor of the special resolution approving the Transaction.

About Repare Therapeutics Inc.

Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s clinical-stage pipeline includes RP-3467, a Phase 1 Polθ ATPase inhibitor; and RP-1664, a Phase 1 PLK4 inhibitor. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.

Additional Information and Where to Find It

The Company intends to file with the SEC and furnish to its shareholders a proxy statement on Schedule 14A, as well as other relevant documents concerning the proposed transaction. The proxy statement will contain important information about the proposed transaction and related matters. Investors and security holders of the Company are urged to carefully read the entire proxy statement (including any amendments or supplements thereto) when it becomes available because it will contain important information about the proposed transactions. A definitive proxy statement will be sent to the shareholders of the Company seeking any required shareholder approvals.

Investors and security holders of the Company will be able to obtain a free copy of the proxy statement, as well as other relevant filings containing information about the Company and the proposed transaction, including materials that will be incorporated by reference into the proxy statement, without charge, at the SEC’s website (http://www.sec.gov) or from the Company by contacting the Company’s Investor Relations at (857) 412-7018, by submitting a contact form on the Company’s website at https://www.reparerx.com/contact/, or by going to the Company’s Investor Relations page on its website at https://ir.reparerx.com/investor-relations and clicking on the link titled “SEC Filings.”

Participants in the Solicitation

The Company and certain of its directors, executive officers and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information regarding the interests of the Company’s directors and executive officers and their ownership of the Company’s common shares is set forth in the Company’s annual report on Form 10-K filed with the SEC on March 3, 2025 and the Company’s proxy statement on Schedule 14A filed with the SEC on April 29, 2025. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests in the proposed transaction, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC in connection with the proposed transaction. Copies of these documents may be obtained, free of charge, from the SEC or the Company as described in the preceding paragraph.

Forward Looking Statements

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable securities laws in Canada. All statements in this news release other than statements of historical facts are forward-looking statements and forward-looking information. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this news release include, but are not limited to, statements regarding the proposed Transaction and any other statements that are not statements of historical fact. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this news release. Each of these forward-looking statements involves risks and uncertainties, many of which are outside of the control of Repare, that could cause the Company’s actual results to differ materially from those expressed or implied by the forward-looking statements, including the consummation of the Transaction and the anticipated benefits thereof. Many factors may cause differences between current expectations and actual results, including: (i) the completion of the Transaction on anticipated terms and timing, including obtaining required shareholder and court approvals, and the satisfaction of other conditions to the completion of the Transaction; (ii) potential litigation relating to the Transaction that could be instituted by or against the Company, Xeno, XOMA Royalty or their respective directors or officers, including the effects of any outcomes related thereto; (iii) significant transaction costs and unknown liabilities associated with the Transaction; and (iv) the risks and uncertainties that will be described in the proxy statement to be prepared by Repare in connection with the potential Transaction (the “Proxy Statement”) and which will be available on the Company’s EDGAR and SEDAR+ profiles. While the list of factors presented here is, and the list of factors to be presented in the Proxy Statement will be, considered representative, no such list should be considered a complete statement of all potential risks and uncertainties related to the Transaction.

Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this news release are identified in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (the “SEC”) and the Autorité des Marchés Financiers (Quebec) (“AMF”) on March 3, 2025, and in other filings made with the SEC and AMF from time to time, including the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit reparerx.com and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at https://www.linkedin.com/company/repare-therapeutics/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251120902912/en/

Investor Relations & Media Contact:

Matthew DeYoung

Investor Relations and Media

Argot Partners

[email protected]

KEYWORDS: United States North America Canada Massachusetts

INDUSTRY KEYWORDS: Science Other Science Biotechnology Research Oncology Health Clinical Trials Other Health

MEDIA: